AUTOLUS THERAPEUTICS LTD (NASDAQ: AUTL)

AUTOLUS THERAPEUTICS LTD

NASDAQ: AUTL (Autolus Therapeutics plc)

Last update: 3 days ago, 10:10AM

1.76

0.11 (6.36%)

Add to watchlist

Previous Close	1.65
Open	1.69
Volume	810,755
Avg. Volume (3M)	1,968,232
Market Cap	467,077,440

Price / Sales	33.53
Price / Book	0.830

52 Weeks Range	1.11 (-37%) — 5.00 (184%)
Earnings Date	8 Aug 2025 - 22 Aug 2025

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Bearish	Bearish
	Biotechnology (Global)	Bearish	Bearish
Stock	Autolus Therapeutics plc	Bullish	Mixed

AIStockmoo Score

1.9

Analyst Consensus	5.0
Insider Activity	NA
Price Volatility	0.5
Technical Moving Averages	0.0
Technical Oscillators	2.0
Average	1.88

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
AUTL	467 M	-	-	0.830
IMCR	2 B	-	-	4.18
GYRE	854 M	-	473.00	13.50
BCYC	577 M	-	-	0.750
MBX	418 M	-	-	1.19
TECX	418 M	-	-	1.34

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Sector	Healthcare
Industry	Biotechnology
% Held by Insiders	18.09%
% Held by Institutions	86.02%

Ownership

Name	Date	Shares Held
Syncona Portfolio Ltd	31 Dec 2024	16,640,720

52 Weeks Range	1.11 (-37%) — 5.00 (184%)
Price Target Range	6.00 (241%) — 10.00 (469%)
High	10.00 (Truist Securities, 469.80%)	Buy
	10.00 (Needham, 469.80%)	Buy
Median	10.00 (469.80%)
Low	6.00 (Wells Fargo, 241.88%)	Buy
Average	8.67 (394.02%)
Total	3 Buy
Avg. Price @ Call	1.42

Firm	Date	Target Price	Call	Price @ Call
Needham	10 Apr 2025	10.00 (469.80%)	Buy	1.14
Truist Securities	01 Apr 2025	10.00 (469.80%)	Buy	1.41
Wells Fargo	21 Mar 2025	6.00 (241.88%)	Buy	1.70

No data within this time range.

Date	Type	Details
29 May 2025	Announcement	Autolus Therapeutics to Participate in Upcoming Investor Conferences
23 May 2025	Announcement	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
14 May 2025	Announcement	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
08 May 2025	Announcement	Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
25 Apr 2025	Announcement	Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
23 Apr 2025	Announcement	Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
22 Apr 2025	Announcement	Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
02 Apr 2025	Announcement	Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
01 Apr 2025	Announcement	Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
24 Mar 2025	Announcement	Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
20 Mar 2025	Announcement	Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
06 Mar 2025	Announcement	Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
05 Mar 2025	Announcement	Autolus Therapeutics to Participate in Upcoming Investor Conferences
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Operating Margin (TTM)	-261,600.00%
Diluted EPS (TTM)	-0.860
Quarterly Revenue Growth (YOY)	681.00%

Total Debt/Equity (MRQ)	69.56%
Current Ratio (MRQ)	10.88
Operating Cash Flow (TTM)	-206.27 M
Levered Free Cash Flow (TTM)	-187.04 M

Return on Assets (TTM)	-25.99%
Return on Equity (TTM)	-81.91%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)